{"id":5041,"date":"2026-07-03T10:54:09","date_gmt":"2026-07-03T00:54:09","guid":{"rendered":"\/eu-uk\/?p=5041"},"modified":"2026-07-03T10:54:09","modified_gmt":"2026-07-03T00:54:09","slug":"orthocell-appoints-exclusive-remplir-distributor-for-thailand","status":"publish","type":"post","link":"\/eu-uk\/blog\/2026\/07\/03\/orthocell-appoints-exclusive-remplir-distributor-for-thailand\/","title":{"rendered":"Orthocell Appoints Exclusive Remplir\u2122 Distributor for Thailand"},"content":{"rendered":"

Orthocell\u00a0Limited (ASX: OCC)\u00a0has appointed medical device distributor\u00a0MediTime\u00a0as\u00a0its exclusive distributor for\u00a0Remplir\u2122 in Thailand, following regulatory approval from the Thai Food and Drug Administration to commence sales into an estimated US$84 million nerve repair market.<\/span>\u00a0<\/span><\/p>\n

MediTime\u00a0is a specialist orthopaedics and sports medicine distributor with established coverage across Thailand\u2019s leading hospitals, medical schools and regional centres, and a strong commercial position in upper extremity orthopaedic surgery.<\/span>\u00a0<\/span><\/p>\n

Its education-led model and established key opinion leader relationships provide\u00a0Orthocell\u00a0with direct access to a core customer base of orthopaedic and plastic surgeons, supporting both surgeon engagement and market adoption.<\/span>\u00a0<\/span><\/p>\n

The appointment also extends\u00a0Orthocell\u2019s\u00a0successful relationship with Device Technologies Group, which supports\u00a0Remplir\u00a0distribution in Australia, New Zealand and Singapore, and now provides regional infrastructure and commercial\u00a0expertise\u00a0behind\u00a0MediTime\u2019s\u00a0operations in Thailand.<\/span>\u00a0<\/span><\/p>\n

Orthocell\u00a0CEO and MD, Paul Anderson, said:<\/span>\u00a0<\/span><\/p>\n

“The appointment of\u00a0MediTime\u00a0as our exclusive distributor in Thailand is an important step in executing our Asian commercialisation strategy for\u00a0Remplir. Thailand represents a high-quality healthcare market with strong underlying demand for advanced nerve repair solutions.<\/span>\u00a0<\/span><\/p>\n

“MediTime’s\u00a0established clinical relationships, education-driven model and national distribution capability make them an ideal partner to support\u00a0the successful introduction\u00a0of\u00a0Remplir.<\/span>\u00a0<\/span><\/p>\n

“Importantly, this appointment further strengthens our successful relationship with Device Technologies Group as we continue to build out our distribution network across Asia.”<\/span>\u00a0<\/span><\/p>\n

Click to read the ASX announcement.<\/a>\u00a0<\/span><\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell Limited (ASX: OCC) has appointed medical device distributor MediTime as its exclusive distributor for Remplir\u2122 in Thailand, following regulatory approval from the Thai Food and Drug Administration to commence sales into an estimated US$84 million nerve repair market. <\/p>\n","protected":false},"author":2,"featured_media":5044,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t